Asia Deal Watch: Strides Obtains 18 US ANDAs From Pharmaceutics
Executive Summary
Deal news from Strides Pharma, Pharmaceutics Intl., Cipla, Wanbury, AstraZeneca, Syntekabio, Arctoris, Mundipharma, Samsung Bioepis…
You may also be interested in...
Strides Optimistic On COVID-19 Antivirals
Optimistic about the potential of repurposing its antivirals portfolio, Strides plans to soon begin bioequivalence studies for favipiravir, a molecule that has found favor as a COVID-19 therapy in a few countries. It also aims to introduce new products to fill the gap left by the withdrawal of ranitidine from the US market.
Strides Optimistic On Prospects Of Antiviral Portfolio For COVID-19
Optimistic about the potential of repurposing its antiviral portfolio, Strides plans to soon begin bioequivalence studies for favipiravir, a molecule that has found favor as a COVID-19 therapy in a few countries. It also aims to introduce new products to fill the gap left by the withdrawal of ranitidine from the US market.
It’s A Deal, Finally: Dr Reddy’s Snaps Up Wockhardt’s Branded Gx Business
Financially stretched Wockhardt sells select branded generic business to Dr Reddy’s for $260m, bringing the curtains down on a much anticipated transaction.